Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Margetuximab [USAN:INN]
RN: 1350624-75-7


  • NCI: A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, anti-HER2 monoclonal antibody MGAH22 may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B). (NCI Thesaurus)
  • Targets CD16A.

Molecular Formula

  • C6484-H10010-N1726-O2024-S42

Classification Code

  • Treatment of Cancer
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Margetuximab [USAN:INN]


  • Immunoglobulin G1, anti-(human neu (receptor)) (human-Mus musculus monoclonal MGAH22 clone ch4D5 heavy chain), disulfide with human-Mus musculus monoclonal MGAH22 clone ch4D5 light chain, dimer
  • Margetuximab
  • MGAH 22
  • MGAH22
  • UNII-K911R84KEW

Registry Numbers

CAS Registry Number

  • 1350624-75-7


  • K911R84KEW

System Generated Number

  • 1350624757